Small-Cell Lung Cancer, Mesothelioma, and Thymoma

As discussed in chapter 3, there are two major subdivisions of lung cancer: small-cell lung cancer (SCLC), for which chemotherapy is the primary treatment, and non–small-cell lung cancer (NSCLC). SCLC is decreasing in frequency in the United States, with recent data showing it represents only 14% of lung cancers. This chapter provides information on the staging and prognosis, pathology and pathophysiology, treatment, and follow-up of long-term survivors of SCLC and concludes with brief discussions on mesothelioma and thymoma.

Chapter 3 provides information on the epidemiology, etiology, screening and prevention, and diagnosis of lung cancer in general and covers NSCLC and carcinoid tumors of the lungs.

Small-cell lung cancer

Staging and prognosis

An international database consisting of 8,088 patients with SCLC was developed by the International Association for the Study of Lung Cancer (IASLC). Their analysis showed that the 7th edition of the AJCC TNM staging system is applicable to SCLC. IASLC recommends that the 7th edition of the AJCC lung cancer should be applied to both NSCLC and SCLC (see chapter 3, Table 1). SCLC has previously been described as either limited (M0) or extensive (M1), although these general terms are inadequate when evaluating the role of surgery. Patients with SCLC who have stages I to III disease, excluding those with a malignant pleural effusion, are classified as having limited disease. These patients constitute approximately one-third of all SCLC patients. The remaining SCLC patients fall into the extensive-disease category, which includes any patient with a malignant pleural effusion or any site of distant disease, such as the brain, liver, adrenal gland, bone, and bone marrow.

The staging of lung cancer must be conducted in a methodical and detailed manner to permit appropriate therapeutic recommendations and to allow comparison of treatment results from different institutions.

Stage is commonly reported as either clinical or pathologic. The former is based on noninvasive (or minimally invasive) tests, whereas the latter is based on tissue obtained during surgery (see chapter 3).

The most important prognostic factor in lung cancer is the stage of disease. Within a given disease stage, the next most important prognostic factors are performance status and recent weight loss. The two scales used to define performance status are the ECOG performance status system and the Karnofsky performance index (see Appendix 1). In short, patients who are ambulatory have a significantly longer survival. Those who have lost ≥ 5% of body weight during the preceding 3 to 6 months have a worse prognosis.

Pathology and pathophysiology

SCLC tends to present with a large central lung mass and associated extensive hilar and mediastinal lymphadenopathy. Clinically evident distant metastases are present in approximately two-thirds of patients at diagnosis. Additionally, data from autopsy examination indicate micrometastatic disease in 63% of patients who died within 30 days of attempted curative resection of SCLC. Thus, it is a systemic disease at presentation in the majority of patients.

SCLC is a small, blue, round cell tumor that is primitive and undifferentiated at the light microscopic level. Electron microscopy demonstrates its neuroendocrine derivation by the presence of dense core granules. The immunohistochemical evidence of neuroendocrine derivation includes positive staining for chromogranin, synaptophysin, and other proteins. The amine precursor uptake and decarboxylation machinery present in the dense core granule leads to the production of biologically active amines and promotes the synthesis of polypeptide hormones such as ADH and ACTH. Paraneoplastic syndromes due to hormone excess result. The most common of these syndromes, syndrome of inappropriate antidiuretic hormone secretion (SIADH), occurs in approximately 10% of patients with SCLC. Hypercortisolism and a Cushing-like syndrome are more rare, seen in only 1% to 2% of patients.

Treatment

Treatment of disease limited to lung parenchyma

Surgery

The majority of patients with SCLC present with advanced-stage disease. In the 5% to 10% of patients whose tumor is limited to the lung parenchyma, very often the diagnosis is established only after the lung mass has been removed. If, however, the histology has been determined by bronchoscopic biopsy or fine-needle aspiration and there is no evidence of metastatic disease following extensive scanning, examination of the bone marrow, and biopsy of the mediastinal lymph nodes, then resection should be performed. Adjuvant chemotherapy is recommended because of the high likelihood of development of distant metastases following surgery.

The surgical approach in SCLC is similar to that used in NSCLC: A lobectomy or pneumonectomy should be followed by a thorough mediastinal lymph node dissection. In a recent retrospective study by Tashi et al, patients with limited-stage SCLC who underwent surgical resection had improved median survivals across all stages. At this time, however, tumor resection in SCLC should be limited to patients who have no evidence of mediastinal or supraclavicular lymph node metastases. Data suggest that patients with SCLC presenting as a solitary pulmonary nodule and proven pathologically to be stage I have a 5-year survival rate of ~70% when treated with resection and adjuvant chemotherapy. 

Treatment of disease limited to the thorax

Approximately one-third of SCLC patients present with disease that is limited to the thorax and can be encompassed within a tolerable radiation portal. In early studies in which either radiation therapy or surgery alone was used to treat such patients, median survival was only 3 to 4 months, and the 5-year survival rate was in the range of 1% to 2%. The reason for the failure of these therapies was both rapid recurrence of intrathoracic tumor and development of distant metastasis.

Chemotherapy

During the 1970s, it became apparent that SCLC was relatively sensitive to chemotherapy. Various combination chemotherapy regimens were used to treat limited SCLC. Although none of the regimens was clearly superior, median survival was approximately 12 months, and the 2-year survival rate was approximately 10% to 15%. It appears that maintenance chemotherapy adds little to survival in patients with limited SCLC.

Chemotherapy plus thoracic irradiation

One of the major advances in treating SCLC in the past 15 years is the recognition of the value of early and concurrent thoracic chemoradiation therapy. This advance was clearly facilitated by the increase in therapeutic index when PE (cisplatin [Platinol]/etoposide) chemotherapy is given with thoracic irradiation, as opposed to older anthracycline- or alkylator-based regimens. Although the major impact from this approach is improved locoregional tumor control, there are hints from randomized trials that early control of disease in the chest can also reduce the risk of distant metastasis.

An Intergroup trial directly compared once-daily vs twice-daily fractionation (45 Gy/25 fractions/5 weeks vs 45 Gy/30 fractions/3 weeks) given at the beginning of concurrent chemoradiation therapy with PE. Initial analysis showed excellent overall results, with median survival for all patients of 20 months and a 40% survival rate at 2 years. With a minimum follow-up of 5 years, survival was significantly better in the twice-daily than in the once-daily irradiation group (26% vs 16%). The only difference in toxicity was a temporary increase in grade 3 esophagitis in patients receiving twice-daily radiation therapy.

Outcomes for patients with limited-stage SCLC have improved significantly over the past 20 years. In an analysis of phase III trials during this period, median survival was 12 months in the control arm in 26 phase III studies initiated between 1972 and 1981, compared with 17 months in studies between 1982 and 1992 (P < .001). Five studies demonstrated a statistically significant improvement in survival in the experimental arm compared with the control arm. Interestingly, all five studies involved some aspect of thoracic radiation therapy (three trials compared chemotherapy alone vs chemoradiation therapy; one compared early vs late radiation therapy; and one compared daily vs twice-daily thoracic radiation therapy). Similarly, data from the SEER database demonstrate that the 5-year survival rate has more than doubled from 1973 to 1996 (5.2% vs 12.2%; P = .0001).

Current recommendations Although important questions remain as to the optimal radiation doses, volumes, and timing with regard to chemotherapy, a reasonable standard is to deliver thoracic irradiation concurrently with PE chemotherapy (cisplatin [60 mg/m² IV on day 1] and etoposide(Drug information on etoposide) [120 mg/ m² IV on days 1 to 3]). An attempt is made to integrate thoracic irradiation as early as possible, during cycle 1 (or 2).

Fried et al performed a meta-analysis evaluating early vs late timing of radiation therapy in limited-stage SCLC. Earlier radiation therapy was defined as that given prior to 9 weeks after initiation of chemotherapy vs late radiation therapy (≥ 9 weeks). Seven trials (n = 1,542 patients) were included in the analysis. They reported a small but significant improvement in 2-year overall survival for early vs late radiation therapy (5.2%; P = .03). This finding is similar to the benefit of adding radiation therapy or prophylactic cranial irradiation (PCI) to chemotherapy. A greater difference was evident for the subset of patients receiving early rather than late hyperfractionated radiation therapy and platinum-based chemotherapy. Hyperfractionated accelerated fractionation should be considered, given the results of the Intergroup 0096 trial. An Intergroup phase III study is under way to compare twice-daily radiation therapy to 45 Gy vs once-daily with radiation therapy to a higher dose (70 Gy) vs a modified regimen combining these strategies (RTOG trial; clinicaltrials.gov ID NCT00632853).

Irradiation can be incorporated sequentially with chemotherapy; however, this approach appears to be inferior to early concurrent therapy and should be reserved for use in patients for whom concurrent approaches are predicted to be excessively toxic.

Takada et al reported on a randomized trial of concurrent vs sequential thoracic radiotherapy in combination with PE in more than 200 patients with limited-stage SCLC; they demonstrated a benefit to concurrent therapy, with a median survival of 27.0 months (30%, concurrent arm) vs 19.7 months (20%, sequential arm; P = .097). Thoracic radiation therapy consisted of 45 Gy over 3 weeks, starting either with the first cycle of PE in the concurrent arm or after the fourth cycle in the sequential arm.

Results of an Intergroup trial indicate that radiation therapy strategies that increase biologic dose can improve tumor local control and survival. Further exploration of accelerated fractionation or conventional doses > 45 Gy is warranted and is being investigated in prospective trials.

Komaki et al have reported both phase I and II data with a "concomitant boost" chemoradiation approach (RTOG 0239). This therapy involves treating the initial large field in daily fractions and boosting the small field to a higher dose (61.2 Gy in 5 weeks), with a second daily fraction on the last 9 days of treatment. The chemotherapy regimen included etoposide and cisplatin(Drug information on cisplatin). The locoregional tumor control rate at 2 years was 80%, though the 2-year survival rate of 37% is not as promising. Severe grade esophagitis occurred in 18% of patients, which is lower than the rate of 27% observed in the accelerated arm of Intergroup 0096.

Movsas et al reported the results of the first Patterns of Care Study (PCS) for lung cancer in the United States. This study was conducted to determine the national patterns of radiotherapy practice in patients treated for nonmetastatic lung cancer in 1998 and 1999. As supported by clinical trials, patients with limited-stage SCLC received chemotherapy plus radiotherapy more often than radiotherapy alone (92% vs 5%; P < .0001). However, only 6% of patients received hyperfractionated (twice-daily) radiotherapy. A total of 22% received PCI, with a median dose of 30 Gy in 15 fractions. Of note, in a more recent follow-up PCS/QRRO study by Komaki et al, the rate of twice-daily radiotherapy increased to about 20% and the rate of PCI usage increased to about 50%.

Interestingly, in 2002 Choi et al reported long-term survival data from their phase I trial assessing chemotherapy with either standard daily radiotherapy or accelerated twice-daily radiotherapy from the CALGB 8837 trial. They previously reported that the maximum tolerated dose was 45 Gy in 30 fractions for twice-daily radiotherapy and > 70 Gy in 35 fractions for once-daily radiotherapy. The 5-year survival estimated (from this phase I trial) for the twice-daily arm was 20%, vs 36% for the once-daily radiotherapy arm. The CALGB and RTOG are accruing patients into a large trial testing three chemoradiation regimens for limited-disease SCLC (CALGB 30610/RTOG 0538). This study includes the accelerated regimen from Intergroup 0096, the concomitant boost from RTOG 0239, and the daily conventional fractionation as studied by Choi et al, with etoposide and cisplatin in all three arms.

Surgery

Although surgical resection is not usually part of the standard therapy for SCLC, the JCOLCSG reported the results of a phase II trial of postoperative adjuvant PE in patients with completely resected stages I–IIIA SCLC. The 5-year survival rates (in a cohort of 62 patients) for pathologic stages I, II, and IIIA SCLC were 69%, 38%, and 40%, respectively.

The role of surgery for stage II or IIIA SCLC has evolved from a number of phase II trials and retrospective case series to include specific indications.They include resection of tumors with mixed histology (containing both SCLC and NSCLC components), salvage surgery for chemoresistant localized SCLC or local relapse after initial response to chemoradiotherapy, or second primary tumors after cure of initial SCLC. Johnson has shown that the rate of second primary NSCLC in patients treated for SCLC can be as high as 2% to greater than 10% per year.

Prospective, randomized trials are ongoing in Europe and Japan to examine the role of surgery as part of multimodality therapy for patients with stages II and IIIA SCLC.

Prophylactic cranial irradiation

Recognition that patients with SCLC are at high risk for development of brain metastases led to the suggestion that they be given PCI to prevent the clinical manifestation of previously present but occult CNS disease. The role of PCI has been controversial. Most trials have shown a reduction in CNS relapse rates with PCI but little effect on survival. There also has been concern about the contribution of PCI to the late neurocognitive deterioration seen in some patients with SCLC, although studies show neurocognitive impairment in many patients with SCLC prior to any treatment.

A meta-analysis of all randomized trials of PCI in patients with SCLC who achieved a complete or near-complete response to induction chemotherapy (alone or combined with thoracic irradiation) showed a statistically significant improvement in survival in patients treated with PCI (20.7% at 3 years vs 15.3% in those not given PCI). The survival improvement with PCI was seen in all patient subgroups, regardless of age, stage of disease, type of induction treatment, or performance status. Approximately 85% of the patients included in the meta-analysis had limited disease, and recommendations for use of PCI have been applied generally to this subgroup. One randomized trial, however, suggests benefit for PCI in patients with responding extensive disease as well.

Given the high incidence of symptomatic brain metastases and the relatively short survival following this event in patients with extensive SCLC, the EORTC randomized 286 patients after response to chemotherapy to receive PCI or not. Irradiation reduced the risk of symptomatic brain metastases, with a hazard ratio of 0.27 (95% CI = 0.16–0.44; P < .001). The cumulative incidence of brain metastases was reduced from 40% in the control group to 15% within 1 year of follow-up. From the time of randomization, patients who were irradiated had an approximate 2-month increase in median survival (6.7 vs 5.4 months) and double the 1-year survival rate (27% vs 13%); progression-free survival was less affected (14.7 vs 12.0 weeks). PCI was reasonably well tolerated, with expected acute effects of headache, nausea and vomiting, and fatigue. Irradiated patients were more frequently given chemotherapy at the time of extracranial disease progression (68% vs 45%). Further, only 59% of patients in the control group who developed brain metastases were treated with whole-brain irradiation. These latter factors may have contributed to the observed survival differences.

A randomized trial reported by Le Pechoux et al in 2009 studied the issue of standard-dose vs higher-dose PCI in patients with limited-stage SCLC. One-half of 720 patients with limited-stage SCLC in complete remission were randomly assigned to receive a standard-dose PCI regimen (25 Gy in 10 fractions). The other half received a higher PCI total dose (36 Gy) delivered using either conventional (18 daily fractions of 2 Gy) or accelerated hyperfractionated (24 fractions in 16 days of 1.5 Gy) radiation. With a median follow-up of 39 months, there was no significant difference in the 2-year incidence of brain metastases between the arms. The 2-year survival was 42% in the standard-dose group and 37% in the higher-dose group (P = .05).The lower overall survival in the higher-dose group was thought to be due to an increase in cancer-related mortality. Overall, this randomized study showed no significant reduction in brain metastases after higher-dose PCI, but there was a significant increase in mortality. Therefore, standard doses of PCI should remain the standard of care in limited-stage SCLC. In reporting on RTOG 0212, Wolfson et al noted that 36 Gy delivered once or twice daily resulted in a greater risk of neurocognitive toxicity than did 25 Gy of PCI. Age > 60 years was significantly predictive for the possibility of this complication.

Current recommendations Patients should be offered PCI after completion of chemotherapy/chemoradiation therapy if they have clear regression of disease and a retained ECOG performance status of 0 to 2. Optimal integration of PCI should occur within 3 to 5 weeks of the last cycle of chemotherapy.

Radiation doses for PCI should probably be in the range of 25 to 30 Gy, with a daily fraction size of 2.0 to 2.5 Gy.

Treatment of extensive disease

As mentioned previously, two-thirds of SCLC patients have extensive disease at diagnosis. Without treatment, median survival in this group of patients is 6 to 8 weeks. Treatment with combination chemotherapy increases the median survival duration to approximately 8 to 10 months.

TABLE 1 Common chemotherapy regimens for SCLC

Induction chemotherapy

The combination of cisplatin or carboplatin(Drug information on carboplatin)/etoposide (see Table 1 for common dose ranges) is considered the standard of care in the United States at this time. This standard is primarily based on therapeutic index, as randomized trials have not demonstrated a survival benefit for this combination relative to the older regimen of cyclophosphamide(Drug information on cyclophosphamide), doxorubicin(Drug information on doxorubicin), and vincristine. The regimen is repeated at 3-week intervals for 4 to 6 courses. In North America, multiple randomized trials of newer cytotoxins replacing etoposide in a doublet with cisplatin, or added to the etoposide/platin base, have not provided a survival benefit. Japanese data that showed a 3.4-month survival advantage for irinotecan(Drug information on irinotecan), as opposed to etoposide, with cisplatin were not confirmed in a trial in the United States, and the North American patients were less tolerant of the irinotecan.

The role of consolidative extracranial irradiation for patients with one to three sites of extensive SCLC is being studied in a randomized, phase II study (RTOG 0937) currently open to accrual. This research is based on an earlier randomized study by Jeremic et al from 1999, indicating that adding consolidative radiation therapy to the treatment of the most favorable subset of patients with extensive SCLC led to improved survival compared with use of chemotherapy alone.

Another large North American study, SWOG S0124, and a trial from Germany comparing irinotecan with etoposide, when both are combined with platinating agents, were recently reported. Both showed equivalence in major efficacy outcomes. A Scandinavian trial with a similar design demonstrated a 1.4-month increase in the median survival rate for irinotecan-based treatment. However, these results are suspect due to an imbalance of elderly patients between the arms and a mandated dose reduction for etoposide in the elderly group. Overall, the data suggest that efficacy is equivalent with either approach. Because of problematic severe diarrhea with irinotecan, the therapeutic index may be improved with etoposide-based therapy.

Treatment of progressive disease

Progressive SCLC is classified based on response and duration of response to initial induction therapy. Patients whose tumors do not regress or progress up to 60 to 90 days following the last cycle of chemotherapy are considered to have refractory disease. Conversely, patients whose tumors respond and who have an unmaintained progression-free interval longer than 60 to 90 days, are deemed to have sensitive relapse. This categorization is based on the probability of objective response to additional cytotoxic therapy, which is uncommon, typically less than 15%, in the case of platin-refractory SCLC.

Topotecan(Drug information on topotecan) (Hycamtin) is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of recurrent disease. Its initial indication in 1998 was for patients with sensitive relapse and was based on similar efficacy compared with an older three-drug regimen. A subsequent trial compared IV administration with oral topotecan capsules, documenting similar efficacy and tolerance.

Most recently, a randomized trial compared oral topotecan with best supportive care in 141 patients with an ECOG performance status of 0 to 2. Patients with both refractory and sensitive disease were accrued. Median survival was nearly doubled on the topotecan arm, 26 vs 14 weeks (P = .0104), as was 6-month survival, 49% vs 26%. Benefit was seen in all subgroups analyzed, including patients with refractory cancer and an ECOG performance status of 2. Despite a low rate of response to topotecan of 7% and typical side effects, treated patients had slower deterioration of quality of life and improved symptom control. Based on these data, in October 2007 the FDA granted topotecan in capsule form a broad indication for treatment of recurrent SCLC.

More limited data with irinotecan suggest that its activity is probably similar to that of topotecan; however, it has never been evaluated in a randomized trial in the recurrent setting. Amrubicin, a synthetic anthracycline, has been studied extensively in recurrent SCLC in Japan and has been approved there. Initial data published in abstract form in North American patients suggest promising response rates with amrubicin in patients with refractory disease and a similar survival benefit as observed with topotecan in sensitive relapse. Amrubicin remains investigational in the United States.

Other cytotoxins, known more for their efficacy in NSCLC, such as docetaxel(Drug information on docetaxel) (Taxotere) and paclitaxel, gemcitabine(Drug information on gemcitabine) (Gemzar), and vinorelbine, do not have high single-agent response rates in therapy-naive SCLC and are not recognized as standard in management.

Integration of biologics in therapy

Ongoing clinical research is focused on integration of molecularly targeted therapy in an effort to make progress in treating this stubborn malignancy. At this time, data from completed trials do not indicate an active strategy with a biologic, whether in combination with induction chemotherapy, as maintenance following induction, or as single agents for recurrent disease.

High-dose chemotherapy plus bone marrow transplantation (BMT) Most phase II trials using high doses of chemotherapy plus BMT appear to show no advantage to the high-dose approach over standard doses of chemotherapy.

Alternating chemotherapy regimens These have been used to overcome drug resistance. In randomized trials, alternating chemotherapy regimens have shown a slight improvement in terms of median survival (4 to 6 weeks) when compared with a single chemotherapeutic regimen but no improvement in long-term survival.

Palliation of local and distant symptoms

Radiation therapy

Many patients with lung cancer have distressing local symptoms at some point in their disease course. These symptoms may arise from airway obstruction by the primary tumor, compression of mediastinal structures by nodal metastases, or metastatic involvement of distant organs. Radiation therapy is effective in palliating most local symptoms as well as symptoms at common metastatic sites, such as in bone and the brain.

In the United States, most radiation oncologists use doses in the vicinity of 30 Gy in 10 fractions for palliative treatment. Data from the United Kingdom suggest that similar efficacy without greater toxicity may be achieved with more abbreviated schedules, such as 17 Gy in two fractions 1 week apart or single fractions of 11 Gy (see chapter 3, Table 8). Such schedules may facilitate the coordination of irradiation and chemotherapy, and they also may reduce patient travel and hospitalization.

Endobronchial irradiation with cobalt-60 or iridium-192 has been used to palliate symptoms arising from partial airway obstruction, including cough, dyspnea, and hemoptysis. The dosimetric advantage of being able to deliver a high radiation dose to the obstructing endobronchial tumor while sparing adjacent normal structures, such as the lungs, spinal cord, and esophagus, has clear appeal, particularly in the patient whose disease has recurred following prior external-beam irradiation. Although good rates of palliation have been reported with endobronchial irradiation, significant complications, including fatal hemoptysis, are seen in 5% to 10% of patients. It remains unclear whether this represents a true treatment complication or symptoms related to the underlying disease.

Other local approaches

Endobronchial irradiation should be considered as only one of several approaches (including laser excision, cryotherapy, and stent placement) in the treatment of patients with symptomatic airway obstruction, and management should be individualized. All of these approaches are more suitable for partial than for complete airway obstruction.

Chemotherapy

Several trials have explored the use of chemotherapy to palliate specific symptoms in patients with lung cancer. In general, these trials have found that rates of symptomatic improvement were considerably higher than objective response rates and were not dissimilar to symptomatic response rates with local radiation therapy. Chemotherapy in the newly diagnosed patient is highly palliative for relief of symptoms related to superior vena cava syndrome, obstructive lung disease, and painful bony metastases. In the patient with recurrent disease, irradiation is more commonly associated with symptomatic relief of these localized problems. Radiation therapy remains the standard of care even for chemotherapy-naive patients with spinal cord compression or symptomatic brain metastasis.

Follow-up of long-term survivors

At present, no standard follow-up protocol exists for patients with cured SCLC or NSCLC. However, at least long-term follow-up should include serial physical examinations once the patient has reached the 5-year mark. There is some controversy about the value of CT scanning or even chest x-rays in the long-term follow-up of these patients.

In this vein, retrospective reviews of the literature have revealed that patients with SCLC appear to have the highest rate of second primary tumor development, as high as 30% over the course of their lifetimes, with some studies reporting annual second primary tumor rates of 5% to 10%. Therefore, the concept of chemoprevention appears to have particular merit in these patients.

Suggested reading

On small-cell lung cancer

Blackhall FH, Shepherd FA: Small cell lung cancer and targeted therapies. Curr Opin Oncol 19:103–108, 2007.

De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24:1057–1063, 2006.

Fried DB, Morris DE, Poole C, et al: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837–4845, 2004.

Glisson BS: Recurrent small cell lung cancer: Update. Semin Oncol 30:72–78, 2003.

Komaki R, Paulus R, Ettinger DS, et al: A phase-II study of accelerated high-dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG 0239. J Clin Oncol 27(15S): abstract 1727, 2009.

Lara PN Jr, Natale R, Crowley J, et al: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535, 2009.

Le Pechoux C, Dunant A, Senan S, et al: Standard dose versus higher dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01: A randomised clinical trial. Lancet Oncol 10:467-474, 2009.

Movsas B, Moughan J, Komaki R, et al: Radiotherapy (RT) Patterns of Care Study (PCS) in lung carcinoma. J Clin Oncol 24:4553–4559, 2003.

O'Brien ME, Ciuleanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–5447, 2006.

Slotman B, Faivre-Finn C, Kramer G, et al: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664–672, 2007.

Tashi T, Aldoss, IT, Gonsalves W, et al: Surgical resection in early limited-stage small-cell lung cancer: Time to rethink?  A retrospective analysis of the VA central cancer registry. J Clin Oncol 29(S458): abstract 7021, 2011.

Wolfson AH, Bae K, Komaki R, et al: Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys Aug 26, 2010 [Epub ahead of print].